Evidence map›Paper›PMID 42627452›Full record

ArticleAdvances in therapy2026

Hyperkalemia Management in the US Cohort of the Prospective, Observational, Real-World TRACK Study.

Elvira O Gosmanova, Javed Butler, Johanna P Contreras, Linda F Fried, Amarnath Kathresal, Wolfgang C Winkelmayer, Hungta Chen, Pooja Desai, Mark Sanford, Eric Wittbrodt and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05408039 (A Prospective, Non-interventional, Longitudinal Study of the Treatment Journey of Adult Patients With Hyperkalemia), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05408039 completednot on this map

A Prospective, Non-interventional, Longitudinal Study of the Treatment Journey of Adult Patients With Hyperkalemia

TypeobservationalSponsorAstraZenecaRan2022 to 2024Enrolled1,331ConditionsHyperkalemia
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elvira O GosmanovaDepartment of Medicine, Albany Stratton VAMC, Albany, NY, USA. elvira.gosmanova@va.gov.
Javed ButlerBaylor Scott & White Research Institute, Dallas, TX, USA.
Johanna P ContrerasDepartment of Cardiology, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine, Mount Sinai, New York, NY, USA.
Linda F FriedRenal Section, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
Amarnath KathresalDurham Nephrology Associates, Durham, NC, USA.
Wolfgang C WinkelmayerSection of Nephrology, Baylor College of Medicine, Houston, TX, USA.
Hungta ChenAstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.
Pooja DesaiAstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.
Mark SanfordAstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.
Eric WittbrodtAstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.
Judith HsiaCPC Clinical Research, Aurora, CO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe Tracking Treatment Pathways in Adult Patients with Hyperkalemia (TRACK) study demonstrated that clinical practice guidelines for hyperkalemia are inconsistently implemented and a conservative approach to management is often preferred. We report additional analyses focusing on routine clinical practice in the USA.

methodsTRACK was an observational prospective cohort study (July 2022-December 2024) including adults in the USA with a recent index hyperkalemia episode (serum potassium [K

resultsThe final cohort included 229 participants, of whom 66.4% and 30.6% had mild (serum K

conclusionsThis study shows that conservative hyperkalemia management and hyperkalemia recurrence are common in routine practice in the USA. Additionally, among individuals with hyperkalemia at baseline, only half of eligible patients with CKD and/or HF were prescribed RAASi therapy. These data highlight the need for effective strategies to treat hyperkalemia and to improve implementation of guideline-directed therapy for CKD and HF. Graphical Abstract available for this article.

trial registrationClinicalTrials.gov identifier, NCT05408039.

Indexed as

Chronic kidney diseaseClinical studyDecision-makingGuideline-directed medical therapyHyperkalemiaPatient-reported outcomesPotassiumUnited States

Identifiers

PMID42627452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.